<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003358</url>
  </required_header>
  <id_info>
    <org_study_id>97-129</org_study_id>
    <secondary_id>MSKCC-97129</secondary_id>
    <secondary_id>NCI-H98-0016</secondary_id>
    <nct_id>NCT00003358</nct_id>
  </id_info>
  <brief_title>Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>Phase I Trial Intraperitoneal Cisplatin With Intraperitoneal Gemcitabine in Patients With Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of cisplatin plus gemcitabine in treating
      patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary
      peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of intraperitoneal (IP) gemcitabine given
      in combination with IP cisplatin in patients with refractory or recurrent ovarian epithelial,
      fallopian tube, or primary peritoneal cancer. II. Determine the safety of this regimen in
      this patient population. III. Determine the pharmacokinetics of IP gemcitabine administered
      with IP cisplatin.

      OUTLINE: This is a dose escalation study of gemcitabine. Patients receive intraperitoneal
      cisplatin on day 1 plus intraperitoneal gemcitabine on days 1, 8, and 15. No treatment will
      be given on day 22. Courses are repeated every 4 weeks. Patients receive up to 4 courses of
      therapy. Dose escalation of gemcitabine continues in cohorts of 3 patients until the maximum
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of
      6 patients experience dose limiting toxicity (DLT). Patients are followed every 3 months for
      2 years, then every 6 months thereafter.

      PROJECTED ACCRUAL: Approximately 3-24 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <primary_completion_date type="Actual">January 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically documented epithelial ovarian carcinoma or
        fallopian tube cancer or primary peritoneal cancer following initial cytoreductive surgery
        and chemotherapy with at least one cisplatin based chemotherapy regimen Must have undergone
        a second assessment procedure (laparoscopy or laparotomy) within 8 weeks of protocol entry,
        and have confirmation of residual disease no greater than 1.0 cm at the end of the
        procedure

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life
        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin less than 3 times upper limit of normal (ULN) SGOT less than
        3 times ULN Alkaline phosphatase less than 3 times ULN Renal: Creatinine less than 1.6
        mg/dL Creatinine clearance at least 50 mL/min Other: Must have a functioning implanted
        subcutaneous intraperitoneal catheter No neuropathy of grade III or greater from prior
        chemotherapy No contraindication to intraperitoneal therapy e.g., intraabdominal infection
        or widespread adhesions

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See
        Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res. 2004 May 1;10(9):2962-7.</citation>
    <PMID>15131031</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

